Sorry, you need to enable JavaScript to visit this website.

PARP1 Activation Induces HMGB1 Secretion Promoting Intestinal Inflammation in Mice and Human Intestinal Organoids

TitlePARP1 Activation Induces HMGB1 Secretion Promoting Intestinal Inflammation in Mice and Human Intestinal Organoids
Publication TypeArticolo su Rivista peer-reviewed
Year of Publication2023
AuthorsVitali, Roberta, Mancuso A.B., Palone Francesca, Pioli Claudio, Cesi Vincenzo, Negroni Anna, Cucchiara S., Oliva S., Carissimi C., Laudadio I., and Stronati Laura
JournalInternational Journal of Molecular Sciences
Volume24
ISSN16616596
Keywords6-dihydrophenanthridin-2-yl)-N, animal, Animals, colitis, cytokine, Cytokines, genetics, high mobility group B1 protein, HMGB1 Protein, human, Humans, inflammation, inflammatory bowel disease, Inflammatory Bowel Diseases, Mice, mouse, N-(oxo-5, N-dimethylacetamide hydrochloride, nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase 1, organoid, Organoids, PARP1 protein, Poly (ADP-Ribose) Polymerase-1
Abstract

Extracellular High-mobility group box 1 (HMGB1) contributes to the pathogenesis of inflammatory disorders, including inflammatory bowel diseases (IBD). Poly (ADP-ribose) polymerase 1 (PARP1) has been recently reported to promote HMGB1 acetylation and its secretion outside cells. In this study, the relationship between HMGB1 and PARP1 in controlling intestinal inflammation was explored. C57BL6/J wild type (WT) and PARP1−/− mice were treated with DSS to induce acute colitis, or with the DSS and PARP1 inhibitor, PJ34. Human intestinal organoids, which are originated from ulcerative colitis (UC) patients, were exposed to pro-inflammatory cytokines (INFγ + TNFα) to induce intestinal inflammation, or coexposed to cytokines and PJ34. Results show that PARP1−/− mice develop less severe colitis than WT mice, evidenced by a significant decrease in fecal and serum HMGB1, and, similarly, treating WT mice with PJ34 reduces the secreted HMGB1. The exposure of intestinal organoids to pro-inflammatory cytokines results in PARP1 activation and HMGB1 secretion; nevertheless, the co-exposure to PJ34, significantly reduces the release of HMGB1, improving inflammation and oxidative stress. Finally, HMGB1 release during inflammation is associated with its PARP1-induced PARylation in RAW264.7 cells. These findings offer novel evidence that PARP1 favors HMGB1 secretion in intestinal inflammation and suggest that impairing PARP1 might be a novel approach to manage IBD. © 2023 by the authors.

Notes

cited By 0

URLhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85156093261&doi=10.3390%2fijms24087096&partnerID=40&md5=15369b79ef4bfe43dfc9cdd1318d6a0d
DOI10.3390/ijms24087096
Citation KeyVitali2023